The relationship between body mass index and cardiopulmonary exercise testing in chronic systolic heart failure - 13/08/11

for the HF-ACTION Investigators
Résumé |
Background |
Cardiopulmonary exercise testing (CPX) in patients with systolic heart failure (HF) is important for determining HF prognosis and helping guide timing of heart transplantation. Although approximately 20% to 30% of patients with HF are obese (body mass index [BMI] >30 kg/m2), the impact of BMI on CPX results is not well established. The objective of this study was to assess the relationship between BMI and CPX variables, including peak oxygen uptake (VO2) at ventilatory threshold, oxygen pulse, and ventilation–carbon dioxide production ratio.
Methods |
Consecutive patients with systolic HF (n = 2,324) enrolled in the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training trial who had baseline BMI recorded were included in this study. Subjects were divided into strata based on BMI: underweight (BMI <18.5 kg/m2), normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25.0-29.9 kg/m2), obese I (BMI 30-34.9 kg/m2), obese II (BMI 35-39.9 kg/m2), and obese III (BMI ≥40 kg/m2).
Results |
Obese III, but not overweight; obese I; or obese II was associated with decreased peak VO2 (mL kg−1 min−1) compared to normal weight status. Increasing BMI category was inversely related to ventilation/carbon dioxide production (VE/VCO2) ratio (P < .0001). On multivariable analysis, BMI was a significant independent predictor of peak VO2 (partial R2 = 0.07, P < .0001) and VE/VCO2 slope (partial R2 = 0.03, P < .0001) in patients with chronic systolic HF.
Conclusions |
Body mass index is significantly associated with key CPX fitness variables in patients with HF. The influence of BMI on the prognostic value of CPX in HF requires further evaluation in longitudinal studies.
Le texte complet de cet article est disponible en PDF.Plan
HF-ACTION is funded by the National Heart Lung and Blood Institute (grants 5U01-HL063747, 5U01-HL066461, HL068973, HL068973, HL066501, HL066482, HL064250, HL066494, HL064257, HL066497 HL068980, HL064265, HL066491, and HL064264. |
|
HF-ACTION is registered: www.clinicaltrials.gov, study number NCT00047437. |
Vol 158 - N° 4S
P. S31-S36 - octobre 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?